Flagship Pioneering launched Expedition Medicines, a startup using artificial intelligence to map the chemistry of small‑molecule binding against proteins historically deemed undruggable. Expedition already disclosed an R&D alliance with Pfizer to apply its platform to cancer targets, signaling large‑cap pharma interest in AI‑driven chemotype discovery. Expedition’s platform reportedly learns from the human proteome to propose novel binding chemistries; the company’s approach aims to shorten lead discovery for challenging targets. For readers: 'Undruggable' refers to protein surfaces or conformations that resist standard small‑molecule binding and require novel chemistries or modalities.